MYOV has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
MYOV has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Myovant Sciences's EBITDA per Share for the three months ended in Dec. 2022 was $-0.51.
During the past 3 years, the average EBITDA Per Share Growth Rate was 20.50% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -2.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of Myovant Sciences was 20.50% per year. The lowest was -23.40% per year. And the median was -4.30% per year.
For the Biotechnology subindustry, Myovant Sciences's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Myovant Sciences's 5-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Myovant Sciences's 5-Year EBITDA Growth Rate falls into.
This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
Myovant Sciences (NYSE:MYOV) 5-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.
Thank you for viewing the detailed overview of Myovant Sciences's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Sumitomo Chemical Co., Ltd. | 10 percent owner | 7-1, NIHONBASHI 2-CHOME, CHUO-KU, TOKYO M0 103-6020 |
Lauren Merendino | officer: Chief Commercial Officer | C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005 |
David C Marek | director, officer: Principal Executive Officer | C/O WEBMD HEALTH CORP., 111 EIGHTH AVENUE, NEW YORK NY 10011 |
Matthew Lang | officer: General Counsel & Corp. Secy. | C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005 |
Ferreira Juan Camilo Arjona | officer: Chief Medical Officer | C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005 |
Uneek Mehra | officer: Principal Financial Officer | C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005 |
Shigeyuki Nishinaka | director | 5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617 |
Nancy Valente | director | C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005 |
Terrie Curran | director | C/O MYOVANT SCIENCES INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018 |
Frank Karbe | officer: Principal Fin'l & Accounting | C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005 |
Kim Sablich | officer: Chief Commercial Officer | C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, BRISBANE CA 94005 |
Hiroshi Nomura | director | C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, BRISBANE CA 94005 |
Sumitovant Biopharma Ltd. | 10 percent owner | C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018 |
Dainippon Sumitomo Pharma Co Ltd | 10 percent owner | 6-8 DOSHOMACHI 2-CHOME, CHUO-KU, OSAKA M0 541-0045 |
Adele M. Gulfo | director | ONE NEENAH CENTER, 4TH FLOOR, P.O. BOX 669, NEENAH WI 54957 |
From GuruFocus
By PRNewswire PRNewswire • 07-15-2022
By Value_Insider Value_Insider • 12-18-2022
By Marketwired • 10-03-2023
By PurpleRose PurpleRose • 08-16-2022
By Marketwired • 09-26-2023
By PRNewswire PRNewswire • 12-16-2022
By PRNewswire PRNewswire • 10-24-2022
By Value_Insider Value_Insider • 11-16-2022
By Ds*** Ds*** • 09-02-2022
By Value_Insider Value_Insider • 12-11-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.